CME Snapshot™ Series
Hitting the Bullseye in NSCLC
Updates on EGFR-Targeting Therapies
Interactive presentation
Overview of the 1st and 2nd Generation EGFR-Targeting Tyrosine Kinase Inhibitors (TKIs)
In this video, Dr. Stefanie Houseknecht outlines the indications, dosage, notable adverse effects, and treatment considerations regarding the first- and second-generation EGFR-targeting TKIs, gefitinib, erlotinib, dacomitinib, and afatinib.
Suggested Readings
Liquid biopsy and non-small cell lung cancer: Are we looking at the tip of the iceberg?
Bonanno L, et al. Br J Cancer. 2022;127(3):383-393.
TATTON: a multi-arm, phase 1b trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Oxnard GR, et al. Ann Oncol. 2020;31(4):507-516.
Amivantamab in EGFR exon 20 insertion-mutated non-small-cell lung cancer progressing on platinum chemotherapy: initial results from the CHRYSALIS phase 1 study.
Park K, et al. J Clin Oncol. 2021;39(30):3391-3402.
Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC.
Ramalingam SS, et al; FLAURA Investigators. N Engl J Med. 2020;382(1):41-50.
A randomized phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Soo RA, et al; ETOP 10-16 BOOSTER Collaborators. Ann Oncol. 2022;33(2):181-192.
Clinical efficacy and prognosis analysis of treatment regimens for EGFR mutant non-small cell lung cancer and brain metastasis: a retrospective study.
Wang H, et al. BMC Cancer. 2023;23(1):289.
Osimertinib combined with bevacizumab as the first-line treatment in non-small cell lung cancer patients with brain metastasis harboring epidermal growth factor receptor mutations.
Zhang L, et al. Thorac Cancer. 2023;14(15):1355-1361.
Treatment outcomes and safety of mobocertinib in platinum-pretreated patients with EGFR exon 20 insertion-positive metastatic non-small cell lung cancer: a phase 1/2 open-label nonrandomized clinical trial.
Zhou C, et al. JAMA Oncol. 2021;7(12):e214761.
Linked Resources
Guidelines
NCCN Guidelines® Insights: Non-Small Cell Lung Cancer, version 2.2023.
Ettinger DS, et al. J Natl Compr Canc Netw. 2023;21(4):340-350.
Clinician Resources
American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Related activities
SnapShot
0.25 CME/AANP/ACPE
Molecular Classification of NSCLC
Hitting the Bullseye in NSCLC: Updates on EGFR-Targeting Therapies
| Faculty: | Heather Wakelee, MD, FASCO; Gerald Berry, MD |
| Release: | 09/29/2023 |
| Expiration: | 09/29/2024 |
SnapShot
0.25 CME/AANP/ACPE
An Overview of EGFR-Targeting Agents
Hitting the Bullseye in NSCLC: Updates on EGFR-Targeting Therapies
| Faculty: | Heather Wakelee, MD, FASCO; Stefanie Houseknecht, PharmD, BCOP |
| Release: | 09/29/2023 |
| Expiration: | 09/29/2024 |
SnapShot
0.25 CME/AANP/ACPE
Treatment Approaches for EGFR+ NSCLC
Hitting the Bullseye in NSCLC: Updates on EGFR-Targeting Therapies
| Faculty: | Heather Wakelee, MD, FASCO; Anjali Sibley MD, MPH |
| Release: | 09/29/2023 |
| Expiration: | 09/29/2024 |
SnapShot
0.25 CME/AANP/ACPE
Overcoming Treatment Challenges in EGFR+ NSCLC
Hitting the Bullseye in NSCLC: Updates on EGFR-Targeting Therapies
| Faculty: | Heather Wakelee, MD, FASCO; Anjali Sibley MD, MPH |
| Release: | 09/29/2023 |
| Expiration: | 09/29/2024 |
